{
  "id": "61f7d745882a024a10000038",
  "type": "factoid",
  "question": "Which disease can be prevented with PfSPZ Vaccine?",
  "ideal_answer": "PfSPZ Vaccine is used for prevention of malaria.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28216244",
    "http://www.ncbi.nlm.nih.gov/pubmed/26324116",
    "http://www.ncbi.nlm.nih.gov/pubmed/34518679",
    "http://www.ncbi.nlm.nih.gov/pubmed/28199305",
    "http://www.ncbi.nlm.nih.gov/pubmed/28362549",
    "http://www.ncbi.nlm.nih.gov/pubmed/29438525",
    "http://www.ncbi.nlm.nih.gov/pubmed/33947856",
    "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
    "http://www.ncbi.nlm.nih.gov/pubmed/33205741",
    "http://www.ncbi.nlm.nih.gov/pubmed/32444192",
    "http://www.ncbi.nlm.nih.gov/pubmed/25917675",
    "http://www.ncbi.nlm.nih.gov/pubmed/29187199",
    "http://www.ncbi.nlm.nih.gov/pubmed/32920641",
    "http://www.ncbi.nlm.nih.gov/pubmed/28223498",
    "http://www.ncbi.nlm.nih.gov/pubmed/33674699",
    "http://www.ncbi.nlm.nih.gov/pubmed/29554084",
    "http://www.ncbi.nlm.nih.gov/pubmed/29943719",
    "http://www.ncbi.nlm.nih.gov/pubmed/27158907",
    "http://www.ncbi.nlm.nih.gov/pubmed/26590432"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Administering 4 stacked priming injections (multi-dose priming) resulted in 40% VE against heterologous CHMI, while dose escalation of PfSPZ using single-dose priming was not significantly protective. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmodium falciparum sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic, purified, cryopreserved PfSPZ) and PfSPZ-CVac (infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria infection (CHMI) in nonimmune adults. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33205741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccine provides protection against P. falciparum infection in malaria-na\u00efve adults. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34518679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to asses",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite vaccines aimed at Pf pre-erythrocytic stages (PfSPZ Vaccine and PfSPZ-CVac), (3) prime boost vaccines that include recombinant DNA, viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26324116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite vaccines aimed at Pf pre-erythrocytic stages (PfSPZ Vaccine and PfSPZ-CVac), (3) prime boost vaccines that include recombinant DNA, viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26590432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria vaccine has demonstrated long",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we aimed to investigate if P. falciparum sporozoite binding and invasion-inhibitory IgM antibodies are induced following immunization of malaria-preexposed volunteers with PfSPZ Vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria, but the features of the antibody response induced by this treatment remain unclear. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " of the candidate human malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria. PfS",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28362549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (sa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We asse",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive ind",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28216244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sterile protection against human malaria by chemoattenuated PfSPZ vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199305",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria. A cri",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32444192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nfections. The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria vaccines because of its unparalleled",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187199",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses admin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "otective efficacy has been demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria chemoprophylaxis. These advance",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25917675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "pared in vitro and in vivo activities of six CSP-specific mAbs derived from human recipients of a recombinant CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 663). RTS,S mA",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33674699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947856",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158907",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223498",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199305",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34518679",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29943719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Collectively, these data suggest durable protection against homologous and heterologous Pf parasites can be achieved with PfSPZ Vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ON: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.FUNDING: US National In",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28216244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28097230",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28216244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed immunization by direct venous inoculation of aseptic, purified, cryopreserved, non-irradiated PfSPZ ('PfSPZ Challenge') to malaria-naive, healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199305",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three doses of 5.12\u2009\u00d7\u2009104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria infection ten weeks after the last dose (group III).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199305",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "malaria"
}